scholarly journals Complaint of Testicular Discomfort in Patient with Esophageal Adenocarcinoma

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Kevin Krughoff ◽  
Alan Schned ◽  
Bing Ren ◽  
Vernon M. Pais
Keyword(s):  
Esophageal Cancer ◽  
Esophageal Adenocarcinoma ◽  
Metastatic Disease ◽  
Cancer Diagnosis ◽  
Older Men ◽  
Physical Exam ◽  
Solitary Metastasis ◽  
New Onset

We report a case of esophageal cancer with solitary metastasis to the testicle in a 71-year-old man. The tumor was picked up on physical exam following new onset complaints of pain and swelling. While most testicular masses in older men are due to lymphoma, this case highlights the need to consider metastatic disease as a source of new symptoms in patients with a recent cancer diagnosis.

scholarly journals Clinically Amyopathic Dermatomyositis Associated with Recurrence of Esophageal Cancer: A Case Report

2021 ◽  
Vol 5 (3) ◽  
pp. 297-300
Author(s):  
Anna Eversman ◽  
Sayeeda Ahsanuddin ◽  
Joel Saltzman ◽  
Paula Silverman ◽  
Mara Beveridge
Keyword(s):  
Esophageal Cancer ◽  
Case Report ◽  
Esophageal Adenocarcinoma ◽  
Clinical Significance ◽  
Amyopathic Dermatomyositis ◽  
Case Presentation ◽  
Skin Changes ◽  
Clinically Amyopathic Dermatomyositis ◽  
Clinical Interest ◽  
New Onset

Background: Approximately 20% of patients displaying skin changes characteristic of dermatomyositis do not develop clinical or enzymatic evidence of muscle inflammation within 6 months of onset, leading to a diagnosis of clinically amyopathic dermatomyositis (CADM). While the association between dermatomyositis and malignancy is well-documented, the clinical significance of CADM is still being elucidated. Case Presentation: We report a case of new-onset CADM associated with recurrent esophageal adenocarcinoma for clinical interest and to add to the limited literature on CADM. Conclusion: To date, there is only one report of concurrent CADM and esophageal cancer. We present this case for clinical interest and to add to the limited literature on CADM.

scholarly journals New onset of type 2 diabetes as a complication after cancer diagnosis: A systematic review

2020 ◽  
Author(s):  
Ara Jo ◽  
Lisa Scarton ◽  
LaToya J. O'Neal ◽  
Samantha Larson ◽  
Nancy Schafer ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Cancer Diagnosis ◽  
After Cancer ◽  
New Onset

scholarly journals Palliative esophagectomy in unexpected metastatic disease: sense or nonsense?

2018 ◽  
Vol 26 (7) ◽  
pp. 552-557 ◽  
Author(s):  
Lieven P Depypere ◽  
Johnny Moons ◽  
Toni E Lerut ◽  
Willy Coosemans ◽  
Hans Van Veer ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Lymph Nodes ◽  
Metastatic Disease ◽  
Palliative Resection ◽  
Oligometastatic Disease ◽  
Group 3 ◽  
Group 2 ◽  
Curative Esophagectomy ◽  
Group 1 ◽  
Single Organ

Background Despite integrated positron emission tomography and computed tomography screening before and after neoadjuvant treatment in patients with locally advanced esophageal cancer, unexpected metastatic disease is still found in some patients during surgery. Should then esophagectomy be aborted or is there a place for palliative resection? Methods Between 2002 and 2015, 681 patients with potentially resectable esophageal cancer were sheduled for neoadjuvant therapy and subsequent esophagectomy. In 552 patients, a potentially curative esophagectomy was performed. In 12 patients, unexpected disease was discovered during surgery but esophagectomy was performed with synchronous resection of metastases; 10 of them had oligometastatic disease (≤4 single-organ metastases). Esophagectomy was not performed in 117 patients (because of disease progression in 50); 14 were also single-organ oligometastatic. Data of 10 single-organ oligometastatic patients who underwent esophageal resection (group 1) were compared those of 10 non-resected but treated counterparts (group 2) and with 228 patients who underwent potentially curative esophagectomy with persistent pathological lymph nodes (group 3). Results Five oligometastatic esophagectomy patients had lung metastases: 1 peritoneal, 2 adrenal, 1 pleural, and 1 pancreatic. Two oligometastatic non-resected patients had lung, 5 liver, and 3 brain metastases. Median overall survival was 21.4, 12.1, and 20.2 months in the respective groups (group 1 vs. group 2  p = 0.042; group 2 vs. group 3  p = 0.002; group 1 vs. group 3  p = 0.88). Conclusions Survival is longer in patients undergoing palliative esophagectomy with unexpected single-organ oligometastatic disease and comparable to survival in patients with persistent pathological lymph nodes. Palliative resection in these patients seems to be justified.

New-onset depression after colorectal cancer diagnosis: a population-based longitudinal study

2021 ◽  
Author(s):  
Simcha Weissman ◽  
Sara Ghoneim ◽  
Ava Sanayei ◽  
Hyder Said ◽  
Samuel Rosenblatt ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Longitudinal Study ◽  
Cancer Diagnosis ◽  
Population Based ◽  
New Onset

Impact of Pancreatic Cancer and Subsequent Resection on Glycemic Control in Diabetic and Nondiabetic Patients

2011 ◽  
Vol 77 (8) ◽  
pp. 1032-1037 ◽  
Author(s):  
Michael A. White ◽  
Steven C. Agle ◽  
Hannah M. Fuhr ◽  
James H. Mehaffey ◽  
Brett H. Waibel ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Glycemic Control ◽  
Cancer Diagnosis ◽  
Univariate Analysis ◽  
Cell Mass ◽  
University Teaching ◽  
Partial Pancreatectomy ◽  
Onset Diabetes ◽  
Number Of Factors ◽  
New Onset

The incidence of new onset or worsening diabetes is surprisingly low in patients after partial pancreatectomy for cancer, leading us to question what factors predict diminished glycemic control in those undergoing resection. All patients undergoing pancreatectomy for cancer at a large, rural university teaching hospital between 1996 and 2010 were identified. The incidence of new onset, or worsening, existing diabetes was determined based on pre and postoperative medication requirement. Univariate analysis was undertaken to identify factors that predict worsened glycemic control. One hundred and one (1 total, 79 Whipple, 21 distal) patients were identified, 41 per cent of which had preexisting diabetes. Nearly half of existing diabetics manifested an increased medication requirement prior to their cancer diagnosis. New onset diabetes occurred in 20 per cent of postoperative patients. Of established diabetics, 34 per cent had either improved glycemic control (9/41) or were cured (5/41) despite the reduction of islet cell mass that occurred with surgery. On univariate analysis, only prolonged hospitalization was associated with worsened glycemic control. Diminished glycemic control is a frequent presenting symptom of pancreatic cancer. Worsened or new onset diabetes is associated with length of stay, which can be influenced by a number of factors including complications and comorbidities.

scholarly journals Esophageal Cancer in Canada: Trends according to Morphology and Anatomical Location

2012 ◽  
Vol 26 (10) ◽  
pp. 723-727 ◽  
Author(s):  
Michael C Otterstatter ◽  
James D Brierley ◽  
Prithwish De ◽  
Larry F Ellison ◽  
Maureen MacIntyre ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Cancer ◽  
Cell Carcinoma ◽  
Esophageal Adenocarcinoma ◽  
Squamous Cell ◽  
Survival Rates ◽  
Relative Survival ◽  
Incidence Rates ◽  
Anatomical Location ◽  
Males And Females

BACKGROUND: Esophageal adenocarcinoma has one of the fastest rising incidence rates and one of the lowest survival rates of any cancer type in the Western world. However, in many countries, trends in esophageal cancer differ according to tumour morphology and anatomical location. In Canada, incidence and survival trends for esophageal cancer subtypes are poorly known.METHODS: Cancer incidence and mortality rates were obtained from the Canadian Cancer Registry, the National Cancer Incidence Reporting System and the Canadian Vital Statistics Death databases for the period from 1986 to 2006. Observed trends (annual per cent change) and five-year relative survival ratios were estimated separately for esophageal adenocarcinoma and squamous cell carcinoma, and according to location (upper, middle, or lower one-third of the esophagus). Incidence rates were projected up to the year 2026.RESULTS: Annual age-standardized incidence rates for esophageal cancer in 2004 to 2006 were 6.1 and 1.7 per 100,000 for males and females, respectively. Esophageal adenocarcinoma incidence rose by 3.9% (males) and 3.6% (females) per year for the period 1986 to 2006, with the steepest increase in the lower one-third of the esophagus (4.8% and 5.0% per year among males and females, respectively). In contrast, squamous cell carcinoma incidence declined by 3.3% (males) and 3.2% (females) per year since the early 1990s. The five-year relative survival ratio for esophageal cancer was 13% between 2004 and 2006, approximately a 3% increase since the period from 1992 to 1994. Projected incidence rates showed increases of 40% to 50% for esophageal adenocarcinoma and decreases of 30% for squamous cell carcinoma by 2026.DISCUSSION: Although esophageal cancer is rare in Canada, the incidence of esophageal adenocarcinoma has doubled in the past 20 years, which may reflect the increasing prevalence of obesity and gastroesophageal reflux disease. Declines in squamous cell carcinoma may be the result of the decreases in the prevalence of smoking in Canada. Given the low survival rates and the potential for further increases in incidence, esophageal adenocarcinoma warrants close attention.

Sign in / Sign up

Export Citation Format

Share Document